HSBC Raises Dechra Pharmaceuticals (LON:DPH) Price Target to GBX 2,950

Dechra Pharmaceuticals (LON:DPH) had its target price upped by research analysts at HSBC from GBX 2,915 ($38.09) to GBX 2,950 ($38.55) in a research note issued to investors on Monday, ThisIsMoney.Co.Uk reports. The brokerage presently has a “hold” rating on the stock. HSBC’s price target would suggest a potential upside of 5.13% from the company’s current price.

Several other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. raised their target price on Dechra Pharmaceuticals from GBX 3,000 ($39.20) to GBX 3,500 ($45.73) and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Royal Bank of Canada raised their target price on Dechra Pharmaceuticals from GBX 2,100 ($27.44) to GBX 2,500 ($32.67) and gave the stock a “sector perform” rating in a research note on Monday, September 2nd.

LON DPH opened at GBX 2,806 ($36.67) on Monday. The business has a 50 day simple moving average of GBX 2,661.54 and a 200 day simple moving average of GBX 2,780.18. Dechra Pharmaceuticals has a one year low of GBX 2,020 ($26.39) and a one year high of GBX 3,080 ($40.25). The stock has a market capitalization of $2.89 billion and a P/E ratio of 93.22. The company has a debt-to-equity ratio of 60.52, a current ratio of 2.47 and a quick ratio of 1.56.

In other Dechra Pharmaceuticals news, insider Tony Griffin sold 20,858 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of GBX 2,789 ($36.44), for a total value of £581,729.62 ($760,132.78). Also, insider Ian Page sold 200,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of GBX 2,917 ($38.12), for a total value of £5,834,000 ($7,623,154.32).

Dechra Pharmaceuticals Company Profile

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

Featured Story: Are sell-side analysts objective?

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.